These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12876957)

  • 1. [Medicinal action and efficacy of neuroleptics].
    Suzuki H; Akimoto T; Gen K; Aoba A
    Ryoikibetsu Shokogun Shirizu; 2003; (38):169-71. PubMed ID: 12876957
    [No Abstract]   [Full Text] [Related]  

  • 2. Receptor pharmacology of neuroleptics: relation to clinical effects.
    Richelson E
    J Clin Psychiatry; 1999; 60 Suppl 10():5-14. PubMed ID: 10340682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of antipsychotic drugs on serotonin receptors.
    Meltzer HY; Nash JF
    Pharmacol Rev; 1991 Dec; 43(4):587-604. PubMed ID: 1685568
    [No Abstract]   [Full Text] [Related]  

  • 4. [Current concepts of the effects of neuroleptics].
    Kostowski W; Płaźnik A
    Psychiatr Pol; 1990; 24(5):28-37. PubMed ID: 1983397
    [No Abstract]   [Full Text] [Related]  

  • 5. [Antidepressive agents: classification and mechanism of action].
    Cuenca E; Alamo C; Coullaut-Jáuregui J
    Rev Clin Esp; 1997 Nov; 197 Suppl 3():44-7. PubMed ID: 9477690
    [No Abstract]   [Full Text] [Related]  

  • 6. Developments in the drug treatment of schizophrenia.
    Reynolds GP
    Trends Pharmacol Sci; 1992 Mar; 13(3):116-21. PubMed ID: 1349447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of serotonin-dopamine antagonists on prepulse inhibition and neurotransmitter contents in the rat cortex.
    Ojima T; Ito C; Sakurai E; Sakurai E; Watanabe T; Yanai K
    Neurosci Lett; 2004 Aug; 366(2):130-4. PubMed ID: 15276232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies towards the identification of a new generation of atypical antipsychotic agents.
    Garzya V; Forbes IT; Gribble AD; Hadley MS; Lightfoot AP; Payne AH; Smith AB; Douglas SE; Cooper DG; Stansfield IG; Meeson M; Dodds EE; Jones DN; Wood M; Reavill C; Scorer CA; Worby A; Riley G; Eddershaw P; Ioannou C; Donati D; Hagan JJ; Ratti EA
    Bioorg Med Chem Lett; 2007 Jan; 17(2):400-5. PubMed ID: 17084080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of brain nondopaminergic mechanisms for the specific action and side effects of neuroleptics].
    Arushanian EB
    Farmakol Toksikol; 1983; 46(1):99-107. PubMed ID: 6130975
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pharmacology of second-generation antipsychotics: a validity of the serotonin-dopamine hypothesis].
    Kuroki T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Oct; 24(5):257-64. PubMed ID: 15658501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of the selective ligands of dopamine and 5-hydroxytryptamine receptors on the tolerance to global cerebral ischemia].
    Kulinskiĭ VI; Gavrilov SS
    Eksp Klin Farmakol; 2006; 69(6):20-3. PubMed ID: 17209458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Which properties make a neuroleptic "atypical"?].
    Gründer G; Vernaleken I; Benkert O
    Nervenarzt; 2001 Nov; 72(11):833-43. PubMed ID: 11758090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
    Kuroki T; Nagao N; Nakahara T
    Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dopaminergic receptors, multiple targets for neuroleptics].
    Martres MP; Sokoloff P; Giros B; Bouthenet ML; Pilon C; Lannfelt L; Schwartz JC
    Ann Med Psychol (Paris); 1992; 150(2-3):119-23. PubMed ID: 1364189
    [No Abstract]   [Full Text] [Related]  

  • 16. Mechanisms of action of anti-psychotic drugs.
    Strange PG
    Biochem Soc Trans; 1999 Feb; 27(2):175-8. PubMed ID: 10093729
    [No Abstract]   [Full Text] [Related]  

  • 17. [The pharmacologist facing the neuroleptics].
    Costentin J
    Encephale; 1991 Jun; 17 Spec No 2():153-7. PubMed ID: 1677889
    [No Abstract]   [Full Text] [Related]  

  • 18. [Antipsychotic drug therapy for patients with behavioral and psychological symptoms of dementia(BPSD)].
    Kudo T
    Seishin Shinkeigaku Zasshi; 2007; 109(7):657-63. PubMed ID: 17969953
    [No Abstract]   [Full Text] [Related]  

  • 19. Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist.
    Dhir A; Kulkarni SK
    Brain Res Bull; 2007 Sep; 74(1-3):58-65. PubMed ID: 17683790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Some pharmacological aspects of neuroleptics (author's transl)].
    Niemegeers CJ
    Encephale; 1981; 7(3):215-24. PubMed ID: 6116591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.